• A Delaware federal jury found Amgen infringed patents tied to HBM Holdings’ Harbour Antibodies unit’s antibody-discovery platform.
• Verdict included a finding of willful infringement. The jury also upheld the patents’ validity.
• Damages awarded totaled USD 20.2 million, matching the full amount sought.
• Willfulness finding allows a request for enhanced damages up to triple, implying potential total damages of about USD 60.6 million.
• The case stems from a patent infringement lawsuit filed in 2021 against Amgen and its unit Teneobio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260615-12201896), on June 15, 2026, and is solely responsible for the information contained therein.